Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Markouli, Mariam, Ullah, Fauzia, Unlu, Serhan, Omar, Najiullah, Lopetegui-Lia, Nerea, Duco, Marissa, Anwer, Faiz, Raza, Shahzad, Dima, Danai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378049/
https://www.ncbi.nlm.nih.gov/pubmed/37504327
http://dx.doi.org/10.3390/curroncol30070467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378049/
https://www.ncbi.nlm.nih.gov/pubmed/37504327
http://dx.doi.org/10.3390/curroncol30070467

Ejemplares similares